Figure 3.
Randomized phase 2 trial of Regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. From Blood Adv. 2017;1(20):1645–9. Used with permission.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.